App-Quantinova.ai

Real-World Infection Rates and Lymphocyte Counts in Patients ≥50 Years with Relapsing-Remitting MS Treated with Subcutaneous Interferon beta-1a or Dimethyl Fumarate

Brooke Hayward - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon beta-1a

Long-Term Reduction in 48-Week Confirmed Disability Progression after 5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

Stephen L Hauser - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ocrelizumab

The Influence of Resiliency on Illness Intrusiveness in Males with Multiple Sclerosis

Lindsay Neto - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Floodlight Open - a Global, Prospective, Open-Access Study to Better Understand Multiple Sclerosis Using Smartphone Technology

Johan van Beek - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Disability and Walking Speed Are Associated with Quality of Life in Not Active Progressive MS

Bruce A C Cree - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ectodermal dysplasia-syndactyly syndrome

N/A

Using Objective and Subjective Measures of Cognition to Predict Activities of Daily Living Abilities Among Persons with Multiple Sclerosis

Ariella Rubel - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

The Effect of Backwards Walking and Forwards Walking on Balance and Lower Extremity Strength in Persons with Multiple Sclerosis: A Pilot Study

Heather M DelMastro - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Comparison of Backwards Vs Forwards Walking on Spatiotemporal Gait Characteristics in Persons with Multiple Sclerosis: A Pilot Study

Edgar Y Wong - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Efficacy in Clinical and MRI Outcomes with Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis (MAGNIFY-MS)

Nicola De Stefano - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Multiple Sclerosis

Cladribine

Pregnancy Outcomes Following Exposure to Ofatumumab in Patients with MS: Results from the Prim Study

Riley Bove - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital anomalies

ofatumumab Intravenous

Frexalimab, a CD40L Inhibitor, in Relapsing Multiple Sclerosis: Results from a Randomized Controlled Phase 2 Trial

Patrick Vermersch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Ofatumumab Effectiveness and Safety in Relapsing Multiple Sclerosis Patients with Breakthrough Disease on Oral Fumarates or Fingolimod: Artios Interim Analysis

Riley Bove - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Fingolimod

A New Mechanism-Driven Framework to Define Progression in MS – a Proposal from the International Advisory Committee on Clinical Trials in MS

Jennifer Graves - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Are Psychosocial Factors Associated with Physical Therapy Goal Accomplishment in Multiple Sclerosis?

Kayla Gomes - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Further Validation of the Multiple Sclerosis Resiliency Scale (MSRS)

Elizabeth S Gromisch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Comparison of Physical Activity between Persons with Multiple Sclerosis with Lower Limb Weakness and Normal Strength

Heather M DelMastro - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CARE-MS I and II Patients By Number of Additional Courses Received Through Year 9

Regina Berkovich - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Alemtuzumab

Effect of Nabiximols Cannabinoid Oromucosal Spray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis (MS)

John DeLuca - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Tetrahydrocannabinol

Prevalence of Serious Adverse Pregnancy Outcomes after Exposure to Interferon Beta before or during Pregnancy: Stratification By Characteristics of Pregnant Women with MS in a Register-Based Cohort Study in Finland and Sweden

Marta Korjagina - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Congenital disorder

Congenital anomalies

Interferon Beta

Potential Weight Changes Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab)

Olivia Wei - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ocrelizumab

Filters

45280 Abstracts